跳至主要内容
临床试验/NCT02392286
NCT02392286终止4 期

A Prospective, Randomized Trial Comparing the Efficacy of Body-weight Based Versus Fixed Corticosteroid Dosage on Remission in Patients With Moderate to Severe Crohn's Disease Flares

Yale University1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2015年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
终止
入组人数
15
试验地点
1
主要终点
Number of Participants in Remission at End of 2 Weeks

研究概览

简要总结

Prospective randomized comparative effectiveness trial designed to compare fixed dosing and weight-based dosing of corticosteroids in patients with Crohn's disease flares.

详细描述

  • Determine if weight-based corticosteroid (1mg/kg daily) induces remission at a greater rate than fixed corticosteroid dosage.
  • Determine if weight-based corticosteroid is associated with greater rate of adverse events than fixed corticosteroid dosage.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Established diagnosis of Crohn's disease
  • Diagnosis of Crohn's flare
  • Decision by treating gastroenterologist to start corticosteroid therapy

排除标准

  • Patients in whom corticosteroid therapy is contraindicated: immunocompromised (active cancer on chemotherapy or radiation treatment), severe liver disease (decompensated cirrhosis, active alcoholic hepatitis), end-stage renal disease on dialysis, AIDS or AIDS-defining illness; myocardial infarction within the past year; NYHA Class 4 heart failure
  • Patients on systemic corticosteroid therapy currently or within the past 8 weeks
  • Patients not on stable doses of immunomodulators or biologics for at least 8 weeks
  • Infectious colitis (e.g., C. difficile, CMV, HSV)
  • Systemic infections (bacteremia, fungal infections)
  • Fulminant Crohn's disease
  • Patients who require imminent surgery
  • Pregnancy
  • Weight <35 kg

研究组 & 干预措施

Weight-based

Active Comparator

Corticosteroid dose weight-based at equivalent to 1mg/kg prednisone daily.

干预措施: Corticosteroid (Drug)

Fixed dose

Active Comparator

Corticosteroid dose fixed at equivalent to 40mg prednisone daily.

干预措施: Corticosteroid (Drug)

结局指标

主要结局

Number of Participants in Remission at End of 2 Weeks

时间窗: 2 weeks

Number of participants with Harvey Bradshaw Index \< 5 at end of 2 weeks. The minimum score obtainable is 0, suggesting absence of disease or remission, while the maximum score obtainable goes beyond 18 points, depending on the number of stools the patient identifies per day (because 1 point is given for each stool in a day, there is no specific maximum score. A higher score represents more severe disease. \<5 is determined to be remission.

次要结局

  • Number of Participants With Response or Remission at End of 12 Weeks(12 weeks)
  • Number of Participants With Response at End of 2 Weeks(2 weeks)
  • Number of Participants With Response or Remission at End of 1 Week(1 week)
  • Number of Participants With Response or Remission at End of 4 Weeks(4 weeks)
  • Number of Participants With Corticosteroid-associated Side Effects(12 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验